Updated Consensus Guidelines on the Management of Phelan-McDermid Syndrome

dc.contributor.authorSrivastava, Siddharth
dc.contributor.authorSahin, Mustafa
dc.contributor.authorBuxbaum, Joseph D.
dc.contributor.authorBerry-Kravis, Elizabeth
dc.contributor.authorValluripalli Soorya, Latha
dc.contributor.authorThurm, Audrey
dc.contributor.authorBernstein, Jonathan A.
dc.contributor.authorAsante-Otoo, Afua
dc.contributor.authorBennett, William E., Jr.
dc.contributor.authorBetancur, Catalina
dc.contributor.authorBrickhouse, Tegwyn H.
dc.contributor.authorBueno, Maria Rita Passos
dc.contributor.authorChopra, Maya
dc.contributor.authorChristensen, Celanie K.
dc.contributor.authorCully, Jennifer L.
dc.contributor.authorDies, Kira
dc.contributor.authorFriedman, Kate
dc.contributor.authorGummere, Brittany
dc.contributor.authorHolder, J. Lloyd, Jr.
dc.contributor.authorJimenez-Gomez, Andres
dc.contributor.authorKerins, Carolyn A.
dc.contributor.authorKhan, Omar
dc.contributor.authorKohlenberg, Teresa
dc.contributor.authorLacro, Ronald V.
dc.contributor.authorLevi, Lori A.
dc.contributor.authorLevy, Tess
dc.contributor.authorLinnehan, Diane
dc.contributor.authorLoth, Eva
dc.contributor.authorMoshiree, Baharak
dc.contributor.authorNeumeyer, Ann
dc.contributor.authorPaul, Scott M.
dc.contributor.authorPhelan, Katy
dc.contributor.authorPersico, Antonio
dc.contributor.authorRapaport, Robert
dc.contributor.authorRogers, Curtis
dc.contributor.authorSaland, Jeffrey
dc.contributor.authorSethuram, Swathi
dc.contributor.authorShapiro, Janine
dc.contributor.authorTarr, Phillip I.
dc.contributor.authorWhite, Kerry M.
dc.contributor.authorWickstrom, Jordan
dc.contributor.authorWilliams, Kent M.
dc.contributor.authorWinrow, Dana
dc.contributor.authorWishart, Brian
dc.contributor.authorKolevzon, Alexander
dc.contributor.departmentPediatrics, School of Medicine
dc.date.accessioned2024-10-17T11:53:14Z
dc.date.available2024-10-17T11:53:14Z
dc.date.issued2023
dc.description.abstractPhelan-McDermid syndrome (PMS) is a genetic condition caused by SHANK3 haploinsufficiency and characterized by a wide range of neurodevelopmental and systemic manifestations. The first practice parameters for assessment and monitoring in individuals with PMS were published in 2014; recently, knowledge about PMS has grown significantly based on data from longitudinal phenotyping studies and large-scale genotype-phenotype investigations. The objective of these updated clinical management guidelines was to: (1) reflect the latest in knowledge in PMS and (2) provide guidance for clinicians, researchers, and the general community. A taskforce was established with clinical experts in PMS and representatives from the parent community. Experts joined subgroups based on their areas of specialty, including genetics, neurology, neurodevelopment, gastroenterology, primary care, physiatry, nephrology, endocrinology, cardiology, gynecology, and dentistry. Taskforce members convened regularly between 2021 and 2022 and produced specialty-specific guidelines based on iterative feedback and discussion. Taskforce leaders then established consensus within their respective specialty group and harmonized the guidelines. The knowledge gained over the past decade allows for improved guidelines to assess and monitor individuals with PMS. Since there is limited evidence specific to PMS, intervention mostly follows general guidelines for treating individuals with developmental disorders. Significant evidence has been amassed to guide the management of comorbid neuropsychiatric conditions in PMS, albeit mainly from caregiver report and the experience of clinical experts. These updated consensus guidelines on the management of PMS represent an advance for the field and will improve care in the community. Several areas for future research are also highlighted and will contribute to subsequent updates with more refined and specific recommendations as new knowledge accumulates.
dc.eprint.versionAuthor's manuscript
dc.identifier.citationSrivastava S, Sahin M, Buxbaum JD, et al. Updated consensus guidelines on the management of Phelan-McDermid syndrome. Am J Med Genet A. 2023;191(8):2015-2044. doi:10.1002/ajmg.a.63312
dc.identifier.urihttps://hdl.handle.net/1805/44033
dc.language.isoen_US
dc.publisherWiley
dc.relation.isversionof10.1002/ajmg.a.63312
dc.relation.journalAmerican Journal of Medical Genetics: Part A
dc.rightsPublisher Policy
dc.sourcePMC
dc.subjectPhelan-McDermid syndrome
dc.subjectSHANK3
dc.subjectAssessment
dc.subjectAutism spectrum disorder
dc.subjectMonitoring
dc.subjectTreatment
dc.titleUpdated Consensus Guidelines on the Management of Phelan-McDermid Syndrome
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Srivastava2023Updated-AAM.pdf
Size:
709.54 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description: